WuXi PharmaTech Co (WX) Tops Q2 View By 7c; WuXi Issues FY08 Revenue Guidance
More News related to WX
- WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
- WuXi PharmaTech (X) Reports Mixed Q3 Earnings; Reaffirms FY08 Outlook
- WuXi PharmaTech Appoints Ying Han to Its Board of Directors
- WuXi PharmaTech Announces Third Quarter 2008 Results
- WuXi PharmaTech Awarded in Deloitte Technology Fast 50 China 2008 List for the Fourth Consecutive Year
More News related to Earnings
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
WuXi PharmaTech Co., Ltd. (NYSE: WX) reports Q2 EPS of $0.21 adjusted, 7 cents better than the analyst estimate of $0.14. Revenues for the quarter were $70.8 million, versus the consensus of $68.32 million.
WuXi Pharma sees FY08 revenue $280 million to $300 million versus consensus of $284.99 million.
Wuxi PharmaTech (Cayman), Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development (R&D) outsourcing company in the People's Republic of China and the United States.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
